matrihealth GmbH receives seed financing for the industrial production of elastin
matrihealth GmbH, an innovative company specializing in the isolation and processing of elastin, has successfully completed a seed financing round. The seven-figure financing sum was provided by two well-known private investors and the Fraunhofer-Gesellschaft. With the capital, matrihealth GmbH is scaling up its production capacities and opening up new market segments.
The matrihealth founding team: Dirk Schuster, Dr. Marco Götze, Dr. Christian Schmelzer and Tobias Hedtke (from left to right).
© Fraunhofer IMWS
Elastin, a naturally occurring structural protein, is known for its extraordinary properties. These make it an essential component of the skin as well as other organs and tissues for which elasticity and resilience are important characteristics. As the protein cannot be reproduced by the body itself, elastin is a sought-after raw material for a wide range of applications in the cosmetics, pharmaceutical, medical and food industries. The matrihealth founding team led by Dr. Christian Schmelzer, Dr. Marco Götze, Tobias Hedtke and Dirk Schuster has developed a method for isolating elastin on an industrial scale and making it available as a highly pure, versatile raw material. With the support of the Fraunhofer Institute for Microstructure of Materials and Systems IMWS and Fraunhofer Venture, matrihealth GmbH was spun off from the Fraunhofer IMWS in October 2022 with a team of three scientists and an economist.
"With the completion of the seed financing and the support of our investors, we will realize our entrepreneurial mission over the next two years," says Dr. Marco Götze, CEO of matrihealth. "Our top priority now is to expand our production capacities in the medium term in order to enable our market entry in the high-volume market segments."
After a successful start in the research market with the soluble elastin hydrolyzate matripure© and ELMA©, the first commercially available elastin for the production of artificial tissue, matrihealth plans to use the new financial resources to set up a production site in Saxony-Anhalt and expand the team.
"Our vision is to use customized solutions to establish elastin as a promising raw material that enables sustainable and innovative applications in various industries," adds Tobias Hedtke, CTO of matrihealth.
By the end of 2025, matrihealth aims to be the first company in the world to produce medical-grade elastin. Building on this, matrihealth is planning to expand its product range to include protein-based nanofiber nonwovens and protein sponges for medical applications in the field of wound treatment.
Note: This article has been translated using a computer system without human intervention. LUMITOS offers these automatic translations to present a wider range of current news. Since this article has been translated with automatic translation, it is possible that it contains errors in vocabulary, syntax or grammar. The original article in German can be found here.
Other news from the department business & finance
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.
Most read news
More news from our other portals
Something is happening in the life science industry ...
This is what true pioneering spirit looks like: Plenty of innovative start-ups are bringing fresh ideas, lifeblood and entrepreneurial spirit to change tomorrow's world for the better. Immerse yourself in the world of these young companies and take the opportunity to get in touch with the founders.
